{"id":"W2770975168","doi":"10.1001/jamaoncol.2017.5029","title":"Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis","year":2017,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Histiocytic Disorders and Treatments","field":"Medicine","cited_by":405,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"National Cancer Institute","keywords":"Vemurafenib; Medicine; V600E; Langerhans cell histiocytosis; Internal medicine; Progression-free survival; Melanoma; Oncology; Adverse effect; Positron emission tomography; Dermatology; Cancer research; Radiology; Chemotherapy; Disease; Mutation; Metastatic melanoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009810934,0.00030631,0.0006952258,0.0002377259,0.0001639452,0.0004095374,0.0002833777,0.0002502218,0.001393206],"category_scores_gemma":[0.0008207904,0.0001361226,0.0004271224,0.0002579848,0.0001750605,0.0003627149,0.0003062816,0.0004074292,0.0001193741],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002777364,"about_ca_system_score_gemma":0.0004046473,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002910253,"about_ca_topic_score_gemma":0.0007857412,"domain_scores_codex":[0.9996227,0.0001569849,0.00005883566,0.00005470051,0.00004578902,0.000060991],"domain_scores_gemma":[0.999441,0.0001230159,0.0002367975,0.00002717976,0.0000323978,0.0001395155],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"case_report","study_design_scores_codex":[0.3245772,0.009344036,0.3460782,0.002414623,0.003084564,0.001992737,0.0001834618,0.002050019,0.07232429,0.0007364391,0.004503136,0.2327113],"study_design_scores_gemma":[0.1223989,0.1772911,0.6449559,0.0002669297,0.002148454,0.008629409,0.0002062446,0.003949964,0.02475904,0.0006722586,0.0146477,0.00007416843],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960109,0.00202798,0.0002906364,0.00007067153,0.00001815532,0.0003102631,0.000351621,0.00001302644,0.0009067963],"genre_scores_gemma":[0.9982452,0.0004168102,0.0003872625,0.0001072966,0.00003331394,0.0001251414,0.000436108,0.000002862761,0.0002459204],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001393206,"threshold_uncertainty_score":0.005188584,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0307705264303714,"score_gpt":0.3246722442241393,"score_spread":0.2939017177937679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}